The divestiture allows CareDx to focus on its core testing services business while receiving $170 million in cash. The strong 48% year-over-year growth in testing services revenue suggests the core business is performing well. The distribution agreement with Eurobio provides ongoing revenue from the divested products.
Price Chart
Executive Summary
CareDx is divesting its lab products business to Eurobio Scientific for $170 million in cash to focus on core testing services, while reporting preliminary Q1 2026 revenue of $118 million with 48% year-over-year growth in testing services revenue. The transaction includes a 6-month transition services agreement and a distribution agreement for North America.
Key Financial Metrics
Key Facts
- Divesting lab products business to Eurobio Scientific for $170 million in cash
- Preliminary Q1 2026 revenue of $118 million, up 39% year-over-year
- Testing services revenue of $91 million, up 48% year-over-year
- Testing volume of 54,900, up 17% year-over-year
- Transition services agreement for at least 6 months at Eurobio's expense
- Eurobio grants CareDx exclusive distribution rights for post-transplant monitoring tests in North America
Financial Impact
$170 million cash proceeds from divestiture, $118 million in Q1 revenue
Risk Factors
- Execution risk in transitioning the divested business
- Potential disruption to operations during the 6-month transition period
- Dependence on Eurobio for future supply of divested products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-043970 |
| Document: tm2611749d1_8k.htm | 0001104659-26-043970 |
| Document: tm2611749d1_ex99-1.htm | 0001104659-26-043970 |
| Document: 0001104659-26-043970-index-headers.html | 0001104659-26-043970 |
| Document: 0001104659-26-043970-index.html | 0001104659-26-043970 |
| Document: 0001104659-26-043970.txt | 0001104659-26-043970 |
| 8-K Data (Synthetic) | 0001104659-26-043970 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Insider Cluster | $44.81 $47.38 | ▲ +5.74% | ▲ +4.52% | $67.15 (+49.85%) |
Aug 4, 2026 8w ago | 144 | $45.50 $47.31 | ▲ +3.98% | ▲ +3.63% | $67.15 (+47.58%) |
Jul 17, 2026 11w ago | Insider Cluster | $39.73 $37.61 | ▼ −5.34% | ▼ −4.65% | $67.15 (+69.02%) |
Jun 16, 2026 15w ago | Insider Cluster | $23.48 $27.13 | ▲ +15.55% | ▲ +16.59% | $67.15 (+185.99%) |
Jun 5, 2026 17w ago | DEFA14A | $21.95 $24.08 | ▲ +9.70% | ▲ +7.59% | $67.15 (+205.92%) |
Apr 28, 2026 22w ago | S-3ASR | $20.80 $20.70 | ▼ −0.48% | ▼ −3.59% | $67.15 (+222.84%) |
Apr 16, 2026 24w ago | 8-K | $22.42 $20.06 | ▼ −10.53% | ▼ −11.51% | $67.15 (+199.51%) |
Feb 25, 2026 31w ago | 8-K/A | $18.46 $19.06 | ▲ +3.25% | ▲ +4.35% | $67.15 (+263.76%) |
Feb 24, 2026 31w ago | 8-K | $18.46 $19.06 | ▲ +3.25% | ▲ +4.35% | $67.15 (+263.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access